Form 4: Jazz Pharmaceuticals Executive Reports Share Transaction

Jazz Pharmaceuticals plc executive Philip L. Johnson reported a transaction involving the withholding of shares to cover tax obligations and an acquisition of shares through an employee stock purchase plan.

Summary

• Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals plc, reported a transaction on June 30, 2026.
• 3,343 ordinary shares were withheld to satisfy tax obligations related to the vesting of restricted stock units.
• An additional 166 ordinary shares were acquired on May 29, 2026, under a Section 423 Employee Stock Purchase Plan.
• Following these transactions, Mr. Johnson beneficially owns 56,431 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions related to equity compensation and employee stock purchase plans, which are standard corporate practices and do not indicate significant positive or negative developments.

Positives

• Acquisition of 166 ordinary shares through an Employee Stock Purchase Plan indicates employee participation and investment in the company.
• The withholding of shares for tax obligations suggests that restricted stock units have vested, which can be a positive sign of performance or tenure.
• Direct beneficial ownership of 56,431 shares by a key executive demonstrates continued commitment to the company.

Negatives

• Withholding of 3,343 shares to cover tax obligations represents a reduction in the executive's direct shareholding, although it's a standard procedure for vested equity awards.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, providing transparency into insider shareholdings and transactions. This filing details standard equity compensation events rather than strategic business updates.

Stakeholder Impact

• Shareholders: Increased transparency into executive share ownership and standard equity compensation practices.
• Employees: The Employee Stock Purchase Plan participation by an executive may signal confidence in the company's stock.
• Management: Standard reporting of equity vesting and tax obligations.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, SEC Filing, Insider Transaction, Philip L. Johnson, Restricted Stock Units, Employee Stock Purchase Plan, Beneficial Ownership